anti-CTLA4
9 abstracts
Abstract
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.Org: Penn State Milton S. Hershey Medical Center, Hershey, PA, Penn State College of Medicine, University Park, PA, University of Toronto,
Abstract
A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.Org: Huntsman Cancer Institute and Department of Neurosurgery, University of Kentucky Markey Cancer Center, University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Center, Division of Cancer Treatment and Diagnosis National Cancer Institute National Institutes of Health, Melanoma Program UPMC Hillman Cancer Center,
Abstract
Combining the potency of a neoantigen-expressing DNA vector, an anti-CTLA-4 antibody, and an attenuated poxvirus in a personalized immunization platform: Preclinical studies of ODI-2001.Org: Odimma Therapeutics, myNEO,
Abstract
Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study.Org: Beilinson Medical Center, EuMelaReg, Military Medical Academy, National Cancer Center Bulgaria, University of Kiel,
Abstract
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.Org: Far Eastern Memorial Hospital, Salem,
Abstract
Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.Org: Massachusetts General Hospital, Brigham and Women's Hospital, Newton,
Abstract
Machine learning (ML)-based quantification of tumor-infiltrating lymphocytes (TIL) and clinical outcomes of patients with melanoma treated with immune-checkpoint inhibitors (ICI).Org: Brigham and Women's Hospital/Massachusetts General Hospital, University Hospital of North Norway, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Dana-Farber Cancer Institute,
Abstract
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, University of Texas MD Anderson Cancer Center,
Abstract
Real-world experience of tebentafusp for uveal melanoma via an Australian access program.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, The Kinghorn Cancer Centre, Darlinghurst, Australia,